Authors: Lourenço, M.C.S.; De Souza, M.V.N.; Pinheiro, A.C.; Ferreira, M.L.; Gonçalves, R.S.B.; Nogueira, T.C.M.; Peralta, M.A.
Source: ARKIVOC, v. XV, p. 181-191, 2007.Publisher: Arkat USA, Inc.
Abstract
Several nicotinic and isoniazid derivatives, most of them containing nitro groups were synthesized by our group, and evaluated for their in vitro
antibacterial activity against Mycobacterium tuberculosis H37Rv using the Alamar Blue susceptibility test and the activityexpressed as the minimum inhibitory concentration (MIC) in mg/mL. The compound 11d exhibited the best result (1.2μg/mL) when compared with first line drugs such as isoniazid (INH) and rifampicin (RIP). Therefore this class of compounds could be a good starting point to develop new lead compounds in the treatment of multi-drug resistant tuberculosis.
Keywords: Tuberculosis, isoniazid, nicotinic acid, analogsDocument Type: Research ArticleDOI: NonePublication date: 1 de Janeiro de 2007
